Advances in Biology and Therapy of Multiple Myeloma

Munshi, Nikhil C. (EDT)/ Anderson, Kenneth C. (EDT)

Editore: Springer Verlag, 2012
ISBN 10: 1461452597 / ISBN 13: 9781461452591
Usato / Hardcover / Quantità: 0
Copie del libro da altre librerie
Mostra tutte le  copie di questo libro

Libro

Purtroppo questa copia non è più disponibile. Di seguito ti proponiamo una lista di copie simili.

Descrizione:

Our orders are sent from our warehouse locally or directly from our international distributors to allow us to offer you the best possible price and delivery time. Codice inventario libreria

Su questo libro:

Book ratings provided by Goodreads):
0 valutazione media
(0 valutazioni)

Riassunto: Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.

From the Back Cover:

Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients.

 

This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Dati bibliografici

Titolo: Advances in Biology and Therapy of Multiple ...
Casa editrice: Springer Verlag
Data di pubblicazione: 2012
Legatura: Hardcover
Condizione libro: New
Edizione: 1.

I migliori risultati di ricerca su AbeBooks

1.

Munshi, Nikhil C.; Kenneth C. Anderson (Eds.):
Editore: New York, Springer, 2013. (2013)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Usato Rilegato Quantità: 1
Valutazione libreria
[?]

Descrizione libro New York, Springer, 2013., 2013. Volume 2: Translational and Clinical Research. X, 287 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Stamped. Codice libro della libreria 2839FB

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra usato
EUR 77,00
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 9,96
Da: Germania a: U.S.A.
Destinazione, tempi e costi

2.

Editore: Springer-Verlag New York Inc., United States (2012)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Rilegato Quantità: 1
Da
The Book Depository US
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Springer-Verlag New York Inc., United States, 2012. Hardback. Condizione libro: New. 2013 ed.. Language: English . Brand New Book. Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM. Codice libro della libreria SPR9781461452591

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 153,80
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

3.

ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Quantità: 1
Da
BWB
(Valley Stream, NY, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Condizione libro: New. Depending on your location, this item may ship from the US or UK. Codice libro della libreria 97814614525910000000

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 154,89
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

4.

Sell Yours Current listings | Items I've sold | List an item for sale | Bulk Upload | Add product | Edit product | Payment History | Rating history | Bulk Status Update | Orders Export Your item will now be listed for sale at $275.99, which includes shipping Advances in Biology and Therapy of Multiple Myeloma Advances in Biology and Therapy of Multiple Myeloma By Nikhil C. Munshi (Edited by) and Kenneth C. Anderson (Edited by) Hardcover (USA), December 2012 1 New or Used from 275.99 List another item for sale
Editore: U.S.A.: Springer (2012)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Rilegato Quantità: 1
Da
Supernew USA
(Bangkok, ., Thailandia)
Valutazione libreria
[?]

Descrizione libro U.S.A.: Springer, 2012. Hardcover. Condizione libro: New. New, 1st Edition . Delivery time is 3-5 business days via either UPS, FedEx, DHL. Premium quality books. Codice libro della libreria 1461452597

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 145,07
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 8,49
Da: Thailandia a: U.S.A.
Destinazione, tempi e costi

5.

Editore: Springer-Verlag New York Inc., United States (2012)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Rilegato Quantità: 1
Da
The Book Depository
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Springer-Verlag New York Inc., United States, 2012. Hardback. Condizione libro: New. 2013 ed.. Language: English . Brand New Book. Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM. Codice libro della libreria SPR9781461452591

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 159,46
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

6.

Editore: Springer (2012)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Rilegato Quantità: 1
Da
Irish Booksellers
(Rumford, ME, U.S.A.)
Valutazione libreria
[?]

Descrizione libro Springer, 2012. Hardcover. Condizione libro: New. book. Codice libro della libreria M1461452597

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 165,89
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
In U.S.A.
Destinazione, tempi e costi

7.

Munshi, Nikhil C.
Editore: Springer (2016)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Paperback Quantità: 1
Print on Demand
Da
Ria Christie Collections
(Uxbridge, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Springer, 2016. Paperback. Condizione libro: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Codice libro della libreria ria9781461452591_lsuk

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 169,20
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 4,33
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

8.

Munshi, Nikhil C.
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Quantità: 4
Da
Paperbackshop-US
(Wood Dale, IL, U.S.A.)
Valutazione libreria
[?]

Descrizione libro 2012. HRD. Condizione libro: New. New Book. Shipped from US within 10 to 14 business days. Established seller since 2000. Codice libro della libreria KS-9781461452591

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 166,17
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 3,39
In U.S.A.
Destinazione, tempi e costi

9.

Anderson, Kenneth C.
Editore: Springer-Verlag New York Inc. (2012)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Quantità: > 20
Print on Demand
Da
Books2Anywhere
(Fairford, GLOS, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Springer-Verlag New York Inc., 2012. HRD. Condizione libro: New. New Book. Delivered from our US warehouse in 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND.Established seller since 2000. Codice libro della libreria IP-9781461452591

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 169,56
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 10,07
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

10.

Editore: Springer-Verlag New York Inc., United States (2012)
ISBN 10: 1461452597 ISBN 13: 9781461452591
Nuovi Rilegato Quantità: 10
Da
Book Depository hard to find
(London, Regno Unito)
Valutazione libreria
[?]

Descrizione libro Springer-Verlag New York Inc., United States, 2012. Hardback. Condizione libro: New. 2013 ed.. Language: English . This book usually ship within 10-15 business days and we will endeavor to dispatch orders quicker than this where possible. Brand New Book. Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM. Codice libro della libreria LIE9781461452591

Maggiori informazioni su questa libreria | Fare una domanda alla libreria

Compra nuovo
EUR 174,69
Convertire valuta

Aggiungere al carrello

Spese di spedizione: GRATIS
Da: Regno Unito a: U.S.A.
Destinazione, tempi e costi

Vedi altre 8 copie di questo libro

Vedi tutti i risultati per questo libro